Targeting of this onco-metabolic pathway via repurposing of eliglustat, a selective small molecule inhibitor of glucosylceramide synthase (UGCG), elicited anti-cancer effects in vitro and attenuated tumor development in an orthotopic syngeneic RM-9 mouse model of prostate cancer. Here, UGCG is linked to neoplasm.